Elutia to Transfer EluPro and CanGaroo Bioenvelopes to Boston Scientific
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 09 2025
0mins
Should l Buy BSX?
Source: NASDAQ.COM
Elutia's Sale Agreement: Elutia Inc. has signed a definitive agreement to sell its EluPro and CanGaroo bioenvelopes to Boston Scientific Corporation for $88 million, aimed at enhancing patient compatibility with implantable medical devices.
Future Plans: CEO Randy Mills expressed confidence in the company's future, highlighting their readiness to leverage their improved balance sheet and commercial capabilities to advance their new technology, NXT-41x, in the breast reconstruction market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise
22 Analyst Rating
22 Buy
0 Hold
0 Sell
Strong Buy
Current: 71.900
Low
94.00
Averages
108.14
High
132.00
Current: 71.900
Low
94.00
Averages
108.14
High
132.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Boston Scientific Expands Buyback Authorization Amid Legal Challenges
- Increased Financial Flexibility: In late February 2026, Boston Scientific entered into a $3.00 billion revolving credit agreement maturing in 2031, significantly enhancing the company's capital flexibility to support growth in cardiovascular and electrophysiology therapies.
- Expanded Buyback Authorization: The board increased the share repurchase authorization to $5.00 billion, reflecting a commitment to capital discipline that could bolster investor confidence following stock pullbacks, despite ongoing legal risks related to electrophysiology litigation.
- Legal Challenges Impact: Boston Scientific is currently facing multiple securities class action lawsuits tied to its U.S. electrophysiology segment, which may exert pressure on its operations and financial performance, necessitating investor attention on how these issues could influence the company's investment narrative.
- Future Outlook: The company projects revenues of $25.4 billion and earnings of $4.8 billion by 2028, indicating potential in high-margin technology investments and acquisition integrations, although execution risks remain a concern in the near term.
See More
Emerging Consolidation Wave in U.S. Markets
- Resurgence of M&A Activity: Over the six months ending March 2026, U.S. merger activity remained robust, with monthly deal counts consistently between 1,000 and 1,300, indicating strong market demand for consolidation despite volatility and macro uncertainty.
- Sector Concentration Trend: Frequent mergers in consumer health, semiconductors, medical devices, and media entertainment suggest that companies in these sectors are consolidating to enhance scale and competitiveness in response to rising costs and technological pressures.
- Clear Strategic Motivations: In consumer products, companies merge brand portfolios to strengthen negotiating power with retailers; semiconductor firms seek scale due to rising R&D costs; and medical technology companies acquire innovative platforms to accelerate product development.
- Emerging Investment Opportunities: As the consolidation wave accelerates, investors should focus on identifying companies that may become acquisition targets, as recognizing integration opportunities within industries could yield significant returns.
See More
Boston Scientific Shareholder Notice Issued
- Shareholder Notice: The Gross Law Firm has issued a notice to shareholders of Boston Scientific (NYSE:BSX), encouraging those who purchased shares during the class period from July 23, 2025, to February 3, 2026, to contact the firm regarding potential lead plaintiff appointment, indicating significant legal risks for the company.
- False Statements Allegations: The complaint alleges that Boston Scientific's management made overwhelmingly positive statements while concealing the true state of its U.S. EP segment's growth, which has severely undermined investor confidence and negatively impacted shareholder interests.
- Disappointing Performance: On February 4, 2026, Boston Scientific reported fourth quarter and full year results that fell short of expectations, particularly in U.S. EP sales, leading to guidance for fiscal 2026 that was well below market expectations, exacerbating investor anxiety about the company's future.
- Stock Price Plunge: Following the disappointing earnings announcement, Boston Scientific's stock price plummeted from $91.62 per share on February 3, 2026, to $75.50 per share on February 4, 2026, marking a dramatic 17.6% decline in just one day, reflecting the market's pessimism about the company's outlook.
See More
Boston Scientific Shareholder Class Action Reminder
- Lawsuit Background: Robbins LLP reminds shareholders of a class action filed on behalf of investors who purchased Boston Scientific Corporation (NYSE: BSX) stock between July 23, 2025, and February 3, 2026, alleging the company misled investors regarding revenue projections.
- Revenue Projection Missteps: The complaint states that Boston Scientific claimed its electrophysiology (EP) market growth would be double that of the market, yet new competitors have entered, diminishing the company's market share and limiting growth potential.
- Stock Price Plunge: Following the February 4, 2026, earnings report, which revealed disappointing U.S. EP sales, Boston Scientific's stock price plummeted over 17%, from $91.62 per share on February 3 to $75.50, reflecting market disappointment in the company's outlook.
- Shareholder Action Guide: Shareholders wishing to serve as lead plaintiffs must submit their papers by May 4, 2026; Robbins LLP offers contingency-based representation, meaning shareholders incur no fees or expenses.
See More
Boston Scientific Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Boston Scientific Corporation is facing a class action lawsuit for alleged violations of federal securities laws, targeting the company and its officers, which involves all securities purchasers between July 23, 2025, and February 3, 2026, highlighting investor concerns over financial transparency.
- False Statement Allegations: The complaint alleges that the company made materially false and misleading statements during the relevant period, failing to disclose that the growth rate of its U.S. electrophysiology segment was unsustainable, severely undermining investor confidence in the company's future.
- Market Reaction: As the company faces adverse trends such as declining procedure volumes, increased competitive pressures, and regulatory reimbursement challenges, investor losses may escalate, reflecting a pessimistic outlook on Boston Scientific's future performance.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by May 4, 2026, indicating that legal action may provide a pathway for recovery of losses, further emphasizing the need for corporate governance and transparency.
See More
Class Action Lawsuit Announced for Boston Scientific Investors
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Boston Scientific (NYSE: BSX) common stock between July 23, 2025, and February 3, 2026, with a deadline of May 4, 2026, for those wishing to serve as lead plaintiff, indicating the legal proceedings are underway.
- Potential Compensation Opportunity: Investors may be entitled to compensation without any out-of-pocket costs through a contingency fee arrangement, which reduces the financial burden on affected shareholders and encourages broader participation in the lawsuit.
- Impact of Misleading Statements: The lawsuit alleges that Boston Scientific made materially false and misleading statements during the class period, leading to investor losses when the company missed net income expectations and provided underwhelming guidance for the first half of 2026, reflecting management's misleading confidence in the electrophysiology segment's growth.
- Law Firm Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and resource advantages in handling similar cases.
See More
Boston Scientific Expands Buyback Authorization Amid Legal Challenges
- Increased Financial Flexibility: In late February 2026, Boston Scientific entered into a $3.00 billion revolving credit agreement maturing in 2031, significantly enhancing the company's capital flexibility to support growth in cardiovascular and electrophysiology therapies.
- Expanded Buyback Authorization: The board increased the share repurchase authorization to $5.00 billion, reflecting a commitment to capital discipline that could bolster investor confidence following stock pullbacks, despite ongoing legal risks related to electrophysiology litigation.
- Legal Challenges Impact: Boston Scientific is currently facing multiple securities class action lawsuits tied to its U.S. electrophysiology segment, which may exert pressure on its operations and financial performance, necessitating investor attention on how these issues could influence the company's investment narrative.
- Future Outlook: The company projects revenues of $25.4 billion and earnings of $4.8 billion by 2028, indicating potential in high-margin technology investments and acquisition integrations, although execution risks remain a concern in the near term.
See More
Emerging Consolidation Wave in U.S. Markets
- Resurgence of M&A Activity: Over the six months ending March 2026, U.S. merger activity remained robust, with monthly deal counts consistently between 1,000 and 1,300, indicating strong market demand for consolidation despite volatility and macro uncertainty.
- Sector Concentration Trend: Frequent mergers in consumer health, semiconductors, medical devices, and media entertainment suggest that companies in these sectors are consolidating to enhance scale and competitiveness in response to rising costs and technological pressures.
- Clear Strategic Motivations: In consumer products, companies merge brand portfolios to strengthen negotiating power with retailers; semiconductor firms seek scale due to rising R&D costs; and medical technology companies acquire innovative platforms to accelerate product development.
- Emerging Investment Opportunities: As the consolidation wave accelerates, investors should focus on identifying companies that may become acquisition targets, as recognizing integration opportunities within industries could yield significant returns.
See More
Boston Scientific Shareholder Notice Issued
- Shareholder Notice: The Gross Law Firm has issued a notice to shareholders of Boston Scientific (NYSE:BSX), encouraging those who purchased shares during the class period from July 23, 2025, to February 3, 2026, to contact the firm regarding potential lead plaintiff appointment, indicating significant legal risks for the company.
- False Statements Allegations: The complaint alleges that Boston Scientific's management made overwhelmingly positive statements while concealing the true state of its U.S. EP segment's growth, which has severely undermined investor confidence and negatively impacted shareholder interests.
- Disappointing Performance: On February 4, 2026, Boston Scientific reported fourth quarter and full year results that fell short of expectations, particularly in U.S. EP sales, leading to guidance for fiscal 2026 that was well below market expectations, exacerbating investor anxiety about the company's future.
- Stock Price Plunge: Following the disappointing earnings announcement, Boston Scientific's stock price plummeted from $91.62 per share on February 3, 2026, to $75.50 per share on February 4, 2026, marking a dramatic 17.6% decline in just one day, reflecting the market's pessimism about the company's outlook.
See More
Boston Scientific Shareholder Class Action Reminder
- Lawsuit Background: Robbins LLP reminds shareholders of a class action filed on behalf of investors who purchased Boston Scientific Corporation (NYSE: BSX) stock between July 23, 2025, and February 3, 2026, alleging the company misled investors regarding revenue projections.
- Revenue Projection Missteps: The complaint states that Boston Scientific claimed its electrophysiology (EP) market growth would be double that of the market, yet new competitors have entered, diminishing the company's market share and limiting growth potential.
- Stock Price Plunge: Following the February 4, 2026, earnings report, which revealed disappointing U.S. EP sales, Boston Scientific's stock price plummeted over 17%, from $91.62 per share on February 3 to $75.50, reflecting market disappointment in the company's outlook.
- Shareholder Action Guide: Shareholders wishing to serve as lead plaintiffs must submit their papers by May 4, 2026; Robbins LLP offers contingency-based representation, meaning shareholders incur no fees or expenses.
See More
Boston Scientific Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Boston Scientific Corporation is facing a class action lawsuit for alleged violations of federal securities laws, targeting the company and its officers, which involves all securities purchasers between July 23, 2025, and February 3, 2026, highlighting investor concerns over financial transparency.
- False Statement Allegations: The complaint alleges that the company made materially false and misleading statements during the relevant period, failing to disclose that the growth rate of its U.S. electrophysiology segment was unsustainable, severely undermining investor confidence in the company's future.
- Market Reaction: As the company faces adverse trends such as declining procedure volumes, increased competitive pressures, and regulatory reimbursement challenges, investor losses may escalate, reflecting a pessimistic outlook on Boston Scientific's future performance.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by May 4, 2026, indicating that legal action may provide a pathway for recovery of losses, further emphasizing the need for corporate governance and transparency.
See More
Class Action Lawsuit Announced for Boston Scientific Investors
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Boston Scientific (NYSE: BSX) common stock between July 23, 2025, and February 3, 2026, with a deadline of May 4, 2026, for those wishing to serve as lead plaintiff, indicating the legal proceedings are underway.
- Potential Compensation Opportunity: Investors may be entitled to compensation without any out-of-pocket costs through a contingency fee arrangement, which reduces the financial burden on affected shareholders and encourages broader participation in the lawsuit.
- Impact of Misleading Statements: The lawsuit alleges that Boston Scientific made materially false and misleading statements during the class period, leading to investor losses when the company missed net income expectations and provided underwhelming guidance for the first half of 2026, reflecting management's misleading confidence in the electrophysiology segment's growth.
- Law Firm Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and resource advantages in handling similar cases.
See More
